secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001493152-26-012372
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.01, 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics change of control: David Lazar sells $11.2M stake; new CEO Junyi Dai appointed
--------------------------------------------------------------------------------

- David Lazar sold 700K Series AAA and 196.8K Series AA Preferred shares to five purchasers for $11.2M.
- Purchasers will own 96.2% of diluted shares post-conversion; may be deemed a group under Exchange Act.
- Four directors resigned, including co-CEO Jeffrey Meckler; David Lazar resigned as co-CEO but remains on board.
- Junyi Dai, 39, appointed CEO and Chairman; previously Managing Director at FLMD Pty Ltd and independent director.
- Company to file resale registration statement within 30 days for 2.064M shares underlying Lazar's retained Series AA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226012372/0001493152-26-012372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226012372/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer